|
Donga Socio Holdings is a holding company that manages a diversified group of businesses across healthcare, logistics, and packaging. Its primary operating subsidiaries include Dong-A Pharmaceutical, which manufactures and sells over-the-counter medicines, health supplements, and consumer health products under the brand BAC; STGen Bio, a contract manufacturing organization specializing in biosimilars and biopharmaceuticals; Yongma Logistics, which provides third-party logistics and cold-chain services; and Dong-A Eco Pack, which produces glass bottles, plastic containers, and bottled water. The group serves domestic and international markets, with its logistics and packaging units supporting clients in the pharmaceutical, beverage, and food industries. Notable products include the BAC vitamin drink and the biosimilar Imudosa. The company was approved as a holding company in 2014. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Conglomerates | Homepage donga.co.kr |
| Sector Industrials | IR page donga.co.kr/investment/ir-2 | |
|
Tags
holding company, over-the-counter medicines, biosimilars, contract manufacturing, third-party logistics, cold-chain logistics, glass packaging, plastic packaging, bottled water, health supplements, Dong-A Pharmaceutical, STGen Bio, Yongma Logistics, Dong-A Eco Pack, BAC, Imudosa, Dong-A Otsuka, Dong-A ST, Coupang, Pulmuone Sammul, Dongwon F&B, Coca-Cola, Woongjin Food
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 636.823B |
| Market cap (USD) | $ 468.691M |
| P/E | 7.37 |
| PEG | 0.07 |
| P/BV | 0.53 |
| P/S | 0.42 |
| P/OCF | 2.57 |
| P/FCF | 3.32 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.3% |
| ROI | 8.0% |
| ROIC | 8.6% |
| Profit margin | 6.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 101.3% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 82.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43T | 1.333T | 1.132T | 1.015T | 881.944B | 783.316B | 769.686B | 707.496B | 690.265B | 726.166B | 704.735B | 630.625B | 570.87B |
| Net profit | 90.945B | 58.022B | 57.99B | 11.153B | 60.271B | 162.345B | 19.764B | -163.977B | 32.543B | 149.051B | 47.883B | 1.716B | 15.568B |
| Free cash flow | 178.13B | 33.43B | 8.593B | 19.351B | 61.025B | 32.644B | 51.85B | 33.197B | 59.47B | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 111B | 82.6B | 90.4B | 91.6B | 93.4B | 102B | 117B | 113B | 125B | 144B |
| ↳ YoY growth | +33.0% | -25.5% | +9.5% | +1.4% | +2.0% | +9.4% | +14.9% | -3.9% | +10.7% | +15.6% |
| ↳ 5y CAGR | +3.3% | +1.4% | +2.3% | -1.6% | +7.3% | +4.5% | +6.4% | +9.1% | ||
| Borrowings, current (KRW) | 332B | 227B | 220B | 286B | 214B | 298B | 383B | 386B | 471B | 396B |
| Borrowings, non-current (KRW) | 29.3B | 171B | 151B | 120B | 207B | 186B | 116B | 202B | 155B | 162B |
| Lease liabilities (KRW) | — | — | — | 62.9B | 66.8B | 54.2B | 52.6B | 104B | 114B | 104B |
| Cash and deposits (KRW) | 95.9B | 179B | 107B | 86.8B | 88.8B | 99.6B | 95.1B | 120B | 117B | 123B |
| Intangible assets (KRW) | 18.4B | 26.5B | 48.1B | 45.7B | 45.1B | 113B | 121B | 132B | 140B | 105B |
| Right-of-use assets (KRW) | — | — | — | 62.1B | 64.9B | 52B | 50.5B | 101B | 108B | 96.7B |
| Net debt (borrowings + leases - cash) (KRW) | -66.7B | 219B | 263B | 382B | 399B | 438B | 457B | 572B | 623B | 540B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 30.5B | 84.5B | 58.3B | 96.8B | 84.6B | 131B | 75.9B | 159B | 83B | 227B |
| Purchases of property, plant and equipment (KRW) | -64.5B | -25B | -25.1B | -44.9B | -51.9B | -70.1B | -56.5B | -150B | -49.6B | -49.3B |
| Purchases of intangible assets (KRW) | -431M | -4.41B | -6.95B | -218M | -3.28B | -8.67B | -22.1B | -9.41B | -26B | -9.35B |
| Dividends paid (cash effect) (KRW) | -6.99B | -6.05B | -6.14B | -6.14B | -6.14B | -9.18B | -9.38B | -12.5B | -11.9B | -10.8B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | -8.39B | — | — | 0.00 | 0.00 | -251M |
| Interest paid (cash effect) (KRW) | -9.46B | -9.77B | -11.9B | -9.85B | -9.2B | -7.46B | -12.3B | -22.7B | -28.3B | -26.3B |
| Income taxes paid (cash effect) (KRW) | -19.9B | -20.6B | -6.35B | -9.19B | -10.6B | -128M | -21.2B | -12.7B | -28.4B | 29.5B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -34.5B | 55.1B | 26.2B | 51.6B | 29.4B | 52.4B | -2.72B | -816M | 7.44B | 169B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | 6.52B | 6.42B | 7.39B | — | — |
| Total comprehensive income (KRW) | 176B | 33.1B | -173B | 19.8B | 158B | — | 23B | 40.6B | 48.5B | 98.6B |
| Comprehensive income to owners (KRW) | 150B | 33.1B | -173B | 19.6B | 158B | 63.2B | 26.2B | 43B | 49B | 98.1B |
| Reported | Apr 2, 2018 | Apr 2, 2018 | Apr 1, 2019 | Mar 30, 2020 | Mar 19, 2021 | Mar 20, 2024 | Mar 21, 2025 | Mar 18, 2026 | Mar 18, 2026 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Oct 16, 2026 | Renamed | Donga Socio Holdings → Dong-A Pharmaceutical |
ETFs Holding Dong-A Pharmaceutical
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVSE | 0.01% | 162 | $ 10.822K | Nov 16, 2026 |
| AVEE | 0.01% | 203 | $ 13.561K | Nov 16, 2026 |
| DFEV | 0.01% | 1,829 | $ 127.024K | Nov 12, 2026 |
| DFSE | 0.01% | 462 | $ 32.086K | Nov 12, 2026 |
| DEXC | 0.00% | 185 | $ 12.848K | Nov 12, 2026 |
| DFEM | 0.00% | 4,469 | $ 310.373K | Nov 12, 2026 |
| DFAE | 0.00% | 3,196 | $ 221.963K | Nov 12, 2026 |
| DFAX | 0.00% | 2,578 | $ 179.043K | Nov 12, 2026 |
| AVEM | 0.00% | 3,595 | $ 240.158K | Nov 16, 2026 |
| AVXC | 0.00% | 121 | $ 8,083.19 | Nov 16, 2026 |